JP2014501286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501286A5 JP2014501286A5 JP2013547686A JP2013547686A JP2014501286A5 JP 2014501286 A5 JP2014501286 A5 JP 2014501286A5 JP 2013547686 A JP2013547686 A JP 2013547686A JP 2013547686 A JP2013547686 A JP 2013547686A JP 2014501286 A5 JP2014501286 A5 JP 2014501286A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- items
- composition according
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 430
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 74
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 62
- 239000002840 nitric oxide donor Substances 0.000 claims description 62
- 229920000136 polysorbate Polymers 0.000 claims description 52
- 229950008882 polysorbate Drugs 0.000 claims description 52
- 229920000642 polymer Polymers 0.000 claims description 51
- 239000004094 surface-active agent Substances 0.000 claims description 48
- 230000000087 stabilizing effect Effects 0.000 claims description 47
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 36
- 229960002722 terbinafine Drugs 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 34
- 210000003491 skin Anatomy 0.000 claims description 33
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 31
- 230000000699 topical effect Effects 0.000 claims description 23
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 239000000230 xanthan gum Substances 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 229940082509 xanthan gum Drugs 0.000 claims description 10
- 235000010493 xanthan gum Nutrition 0.000 claims description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 9
- 229930064664 L-arginine Natural products 0.000 claims description 9
- 235000014852 L-arginine Nutrition 0.000 claims description 9
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 7
- 235000019743 Choline chloride Nutrition 0.000 claims description 7
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 7
- 239000001110 calcium chloride Substances 0.000 claims description 7
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 7
- 229960003178 choline chloride Drugs 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 7
- 229940068977 polysorbate 20 Drugs 0.000 claims description 7
- 210000000434 stratum corneum Anatomy 0.000 claims description 7
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 5
- 238000000034 method Methods 0.000 description 41
- 229940121375 antifungal agent Drugs 0.000 description 38
- 150000003852 triazoles Chemical class 0.000 description 38
- 239000003429 antifungal agent Substances 0.000 description 26
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 24
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 150000003841 chloride salts Chemical class 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 18
- 235000019901 KELTROL® Nutrition 0.000 description 17
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 12
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 12
- 239000005642 Oleic acid Substances 0.000 description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 229960000541 cetyl alcohol Drugs 0.000 description 12
- 229940075529 glyceryl stearate Drugs 0.000 description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 12
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 12
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 11
- 229940032094 squalane Drugs 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 8
- 239000006210 lotion Substances 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 6
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229960002337 magnesium chloride Drugs 0.000 description 4
- 229960002816 potassium chloride Drugs 0.000 description 4
- 229960002668 sodium chloride Drugs 0.000 description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical group CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- AEKNYBWUEYNWMJ-QWOOXDRHSA-N Pramiconazole Chemical group O=C1N(C(C)C)CCN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(CO3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 AEKNYBWUEYNWMJ-QWOOXDRHSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 229960001589 posaconazole Drugs 0.000 description 1
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical group O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 1
- 229950001086 pramiconazole Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229960004740 voriconazole Drugs 0.000 description 1
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428053P | 2010-12-29 | 2010-12-29 | |
| US201061428213P | 2010-12-29 | 2010-12-29 | |
| US61/428,213 | 2010-12-29 | ||
| US61/428,053 | 2010-12-29 | ||
| PCT/US2011/067992 WO2012092527A1 (en) | 2010-12-29 | 2011-12-29 | Delivery of treatments transdermally for fungal infections and other indications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501286A JP2014501286A (ja) | 2014-01-20 |
| JP2014501286A5 true JP2014501286A5 (enExample) | 2015-02-19 |
Family
ID=46383542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547686A Pending JP2014501286A (ja) | 2010-12-29 | 2011-12-29 | 真菌感染症および他の適応症に対する処置の経皮的送達 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140004176A1 (enExample) |
| EP (1) | EP2658552A4 (enExample) |
| JP (1) | JP2014501286A (enExample) |
| CN (2) | CN103429246A (enExample) |
| WO (1) | WO2012092527A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
| US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
| CA2563670C (en) * | 2004-04-19 | 2014-09-16 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| US12138268B2 (en) | 2009-06-24 | 2024-11-12 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| EP2445493A1 (en) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topical composition containing naproxen |
| EP2445492B1 (en) | 2009-06-24 | 2016-09-28 | Strategic Science & Technologies, LLC | Topical composition containing ibuprofen |
| US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
| WO2012092523A1 (en) | 2010-12-29 | 2012-07-05 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
| CN114668851B (zh) | 2010-12-29 | 2024-11-01 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
| WO2016010988A1 (en) | 2014-07-14 | 2016-01-21 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
| WO2017019614A1 (en) * | 2015-07-28 | 2017-02-02 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
| GB201605127D0 (en) * | 2016-03-25 | 2016-05-11 | Blueberry Therapeutics Ltd | Composition and methods of treatment |
| JP6992057B2 (ja) | 2016-06-10 | 2022-01-13 | クラリティ コスメティックス インコーポレイテッド | 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法 |
| AU2017363973B2 (en) * | 2016-11-28 | 2022-03-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of oral infectious diseases |
| CN108451900A (zh) * | 2018-05-08 | 2018-08-28 | 钟啟铭 | 一种治疗手足部皮肤角质细菌感染的药材及其加工方法 |
| CN111658601A (zh) * | 2020-06-12 | 2020-09-15 | 浙江普利药业有限公司 | 伏立康唑外用制剂及其制备方法 |
| CN116019807A (zh) * | 2023-01-13 | 2023-04-28 | 南京瑞孚医药科技有限公司 | 治疗真菌感染的外用药物组合及其制备方法、应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
| CA2563670C (en) * | 2004-04-19 | 2014-09-16 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
| FR2904549B1 (fr) * | 2006-08-03 | 2012-12-14 | Sederma Sa | Composition comprenant de la sarsasapogenine |
| RU2009117468A (ru) * | 2006-10-12 | 2010-11-20 | Рото Фармасьютикал Ко., Лтд. (Jp) | Наружный препарат для кожи |
| MX337408B (es) * | 2007-03-22 | 2016-03-03 | Berg Llc | Formulaciones topicas que tienen biodisponibilidad aumentada. |
| HUE029707T2 (en) * | 2007-08-27 | 2017-03-28 | Nihon Nohyaku Co Ltd | Anti-fungal dermatitis |
| EP2445492B1 (en) * | 2009-06-24 | 2016-09-28 | Strategic Science & Technologies, LLC | Topical composition containing ibuprofen |
-
2011
- 2011-12-29 CN CN2011800686133A patent/CN103429246A/zh active Pending
- 2011-12-29 WO PCT/US2011/067992 patent/WO2012092527A1/en not_active Ceased
- 2011-12-29 EP EP11853913.9A patent/EP2658552A4/en not_active Withdrawn
- 2011-12-29 CN CN201610111896.XA patent/CN105748450A/zh active Pending
- 2011-12-29 US US13/977,546 patent/US20140004176A1/en not_active Abandoned
- 2011-12-29 JP JP2013547686A patent/JP2014501286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501286A5 (enExample) | ||
| JP2014501284A5 (enExample) | ||
| JP2014504592A5 (enExample) | ||
| JP2014501285A5 (enExample) | ||
| JP2014501283A5 (enExample) | ||
| RU2012102284A (ru) | Топическая композиция, содержащая ибупрофен | |
| JP2022174292A5 (enExample) | ||
| JP2012062328A5 (enExample) | ||
| AU2006339841B2 (en) | Pharmaceutical composition for external use | |
| ES2279901T3 (es) | Emplasto comprendiendo sertaconazol para el tratamiento de disfunciones o enfermedades de las uñas. | |
| US20170112780A1 (en) | Pharmaceutical composition for application to nail | |
| JP2016135812A5 (enExample) | ||
| RU2007119380A (ru) | Косметические продукты, предназначенные для ухода за собой, включающие соли дигидроксипропилтри (c1-c3алкил) аммония | |
| JP2012197300A5 (enExample) | ||
| TWI454249B (zh) | 用於治療或預防甲癬或足癬之壓敏膠黏劑基質藥貼裝置 | |
| JP2002512187A (ja) | 爪真菌病の処置のための局所製剤 | |
| EP0792137A1 (en) | Antifungal treatment of nails | |
| JP2002509874A (ja) | 塩基性アルカリ金属塩を用いて活性物質塩を遊離塩基に変換する経皮治療システムの製造方法 | |
| WO2007102243A1 (ja) | 外用の医薬組成物 | |
| JP2011116787A5 (enExample) | ||
| CN114668851A (zh) | 勃起功能障碍和其它适应症的治疗 | |
| CN103429246A (zh) | 真菌感染和其它适应症的治疗的透皮递送 | |
| ES2244373T3 (es) | Emplasto de uso topico que contiene heparina y diclofenaco. | |
| JP2016033168A (ja) | Cox−2阻害剤および関連化合物、ならびにそれらを送達するためのシステムおよび方法 | |
| JP2012508251A5 (enExample) |